Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Melanoma 1Lymphoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 18Carboplatin 14Topotecan 8liposomal doxorubicin 6Cyclophosphamide 5Cisplatin 5Gemcitabine 4Docetaxel 4oregovomab 3Immunoenzyme Techniques 3Etoposide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Stem Cell Transplantation 2STA 9090 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Fulvestrant 2Fluorodeoxyglucose F18 2Flow Cytometry 2Filgrastim 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Ovarian Epithelial × 1-dodecylpyridoxal × Clear all
NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Pfizer

Phase 1/2 Terminated
10 enrolled 21 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01281254 2017-12-02

TRINOVA-2

Amgen

Phase 3 Terminated
223 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡